Document Detail

Risk of subsequent cancer following a primary CNS tumor.
MedLine Citation:
PMID:  23392847     Owner:  NLM     Status:  MEDLINE    
Improvements in survival among central nervous system (CNS) tumor patients has made the risk of developing a subsequent cancer an important survivorship issue. Such a risk is likely influenced by histological and treatment differences between CNS tumors. De-identified data for 41,159 patients with a primary CNS tumor diagnosis from 9 Surveillance, Epidemiology and End Results (SEER) registries were used to calculate potential risk for subsequent cancer development. Relative risk (RR) and 95 % confidence interval (CI) of subsequent cancer was calculated using SEER*Stat 7.0.9, comparing observed number of subsequent cancers versus expected in the general United States population. For all CNS tumors studied, there were 830 subsequent cancers with a RR of 1.26 (95 % CI, 1.18-1.35). Subsequent cancers were observed in the CNS, digestive system, bones/joints, soft tissue, thyroid and leukemia. Radiotherapy was associated with an elevated risk, particularly in patients diagnosed with a medulloblastoma/primitive neuroectodermal tumor (MPNET). MPNET patients who received radiotherapy were at a significant risk for development of cancers of the digestive system, leukemia, bone/joint and cranial nerves. Glioblastoma multiforme patients who received radiotherapy were at lower risks for female breast and prostate cancers, though at an elevated risk for cancers of the thyroid and brain. Radiotherapy is associated with subsequent cancer development, particularly for sites within the field of radiation, though host susceptibility and post-treatment status underlie this risk. Variation in subsequent cancer risk among different CNS tumor histological subtypes indicate a complex interplay between risk factors in subsequent cancer development.
Kyle Strodtbeck; Andrew Sloan; Lisa Rogers; Paul Graham Fisher; Duncan Stearns; Laura Campbell; Jill Barnholtz-Sloan
Related Documents :
24084407 - Outcomes of a head and neck cancer screening clinic.
23496227 - Blood-based peptide, genetic, and epigenetic biomarkers for diagnosing gastrointestinal...
25139937 - Association of leukocyte mitochondrial dna copy number with colorectal cancer risk: res...
23045537 - Patient navigation improves cancer diagnostic resolution: an individually randomized cl...
22191007 - Reed's syndrome: a case of multiple cutaneous and uterine leiomyomas.
10229917 - Modulation of genotoxic and related effects by carotenoids and vitamin a in experimenta...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural     Date:  2013-02-08
Journal Detail:
Title:  Journal of neuro-oncology     Volume:  112     ISSN:  1573-7373     ISO Abbreviation:  J. Neurooncol.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-26     Completed Date:  2013-09-10     Revised Date:  2014-04-02    
Medline Journal Info:
Nlm Unique ID:  8309335     Medline TA:  J Neurooncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  285-95     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Central Nervous System Neoplasms / complications*,  epidemiology
Child, Preschool
Cohort Studies
Follow-Up Studies
Infant, Newborn
Neoplasm Staging
Neoplasms, Second Primary / epidemiology,  etiology*
Risk Factors
SEER Program
United States / epidemiology
Young Adult
Grant Support
P30 CA043703/CA/NCI NIH HHS; P30 CA043703/CA/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Harmine hydrochloride inhibits Akt phosphorylation and depletes the pool of cancer stem-like cells o...
Next Document:  Expression of aquaporin 5 and the AQP5 polymorphism A(-1364)C in association with peritumoral brain ...